Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients

被引：5

作者：

Locke, Jayme E. ^{[1
]}

Singer, Andrew L. ^{[1
]}

机构：

[1] Johns Hopkins Med Inst, Dept Surg, Div Transplantat, Baltimore, MD 21205 USA

来源：

HEPATIC MEDICINE-EVIDENCE AND RESEARCH | 2011年 / 3卷

关键词：

liver transplantation; immunosuppression; acute cellular rejection; patient and graft survival; hepatitis C recurrence;

D O I：

10.2147/HMER.S13682

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The introduction of calcineurin inhibitor (CNI) based immunosuppression has revolutionized the field of liver transplantation by dramatically reducing the incidence of acute cellular rejection and prolonging patient and allograft survival. However, the introduction of CNIs has also come at the price of increased patient morbidity, particularly with regard to the well-known nephrotoxic effects of the medications. In an effort to minimize the adverse effects, immunosuppression regimen have evolved to include the use of various induction agents and purine synthesis inhibitors to limit the dose of CNI necessary to achieve low acute cellular rejection rates. Careful assessments of risks and benefits are needed as these newer agents have their own side effect profiles. In addition, the impact of newer immunosuppression regimen on hepatitis C (HCV) recurrence has not been completely elucidated. This review will provide an overview of the most common immunosuppression regimen used in liver transplantation and discuss their impact on acute cellular rejection, patient and allograft survival, and HCV recurrence.

引用

页码：53 / 62

页数：10

共 141 条

[11] Steroids in recurrent hepatitis C following liver transplantation: Pitfall or panacea? [J].

Brown, Robert S., Jr. .

JOURNAL OF HEPATOLOGY, 2007, 47 (06) :741-743

[12] Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study [J].

Budde, K ;

Curtis, J ;

Knoll, G ;

Chan, L ;

Neumayer, HH ;

Seifu, Y ;

Hall, M .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (02) :237-243

[13]

BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110

[14] Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data [J].

Cai, Junchao ;

Terasaki, Paul I. .

TRANSPLANTATION, 2010, 90 (12) :1511-1515

[15] Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients [J].

Calmus, Y ;

Scheele, JR ;

Gonzalez-Pinto, I ;

Jaurrieta, EJ ;

Klar, E ;

Pageaux, GP ;

Scudamore, CH ;

Cuervas-Mons, V ;

Metselaar, HJ ;

Prestele, H ;

Girault, D .

LIVER TRANSPLANTATION, 2002, 8 (02) :123-131

[16] Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients [J].

Calne, R ;

Friend, P ;

Moffatt, S ;

Bradley, A ;

Hale, G ;

Firth, J ;

Bradley, J ;

Smith, K ;

Waldmann, H .

LANCET, 1998, 351 (9117) :1701-1702

[17]

CALNE RY, 1985, LANCET, V1, P1342

[18] Prope tolerance: A step in the search for tolerance in the clinic [J].

Calne, RY .

WORLD JOURNAL OF SURGERY, 2000, 24 (07) :793-796

[19]

CALNE RY, 1981, ANN CLIN RES, V13, P327

[20] Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus [J].

Casas-Melley, AT ;

Falkenstein, KP ;

Flynn, LM ;

Ziegler, VL ;

Dunn, SP .

PEDIATRIC TRANSPLANTATION, 2004, 8 (04) :362-366

← 1 2 3 4 5 6 7 8 9 10 →